← PCSK9 inhibitors × all-cause mortality

ArticleCardiovascular diabetology2022

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.

Xing Wang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 54,311 people · 2022

Randomised comparison

Reduced deaths

−17%−28% to −5%

Bigger than 5 in 10 for all-cause mortality

As reported

RR 0.83, 95% CI 0.72–0.95 · the paper's word: All-cause mortality

Not counted

Increased deaths

+26%+4% to +52%

Bigger than 6 in 10 for all-cause mortality

As reported

RR 1.26, 95% CI 1.04–1.52 · the paper's word: All-cause mortality

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower adverse events & safety

−6%−10% to −1%

Bigger than 2 in 10 for adverse events & safety

As reported

RR 0.94, 95% CI 0.90–0.99

Three numbers in the abstract

the abstract, start to end

… mortality compared with control (RR 0.83, 95% CrI 0.72-0.95).

… mortality compared with alirocumab (RR 1.26, 95% CrI 1.04-1.52).

… risk of serious adverse events (RR 0.94, 95% CrI 0.90-0.99).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
RR 0.830.72–0.95
All-cause mortality
RR 1.261.04–1.52
Adverse events & safety
RR 0.940.90–0.99
PCSK9 inhibitorsAll-cause mortalityAdverse events & safety

PCSK9 inhibitors × all-cause mortalityhelps?replicated

unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

40 papers cite it

2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35706032